Twenty patients with complex partial status epilepticus were identified retrospectively from a specialist neurology hospital. Seventeen patients experienced recurrent episodes of complex partial status epilepticus, often occurring at regular intervals, usually over many years, and while being treated with effective anti-epileptic drugs. No unifying cause for the recurrences, and no common epilepsy aetiologies, were identified. In spite of the frequency of recurrence and length of history, none of the patients showed any marked evidence of cognitive or neurological deterioration. Complex partial status epilepticus is more common than is generally recognised, should be differentiated from other forms of non-convulsive status, and is often difficult to treat. 
Accepted 18 November 1993 Complex partial status epilepticus (CPSE) with EEG evidence was first described in 1956,' and a number of cases have been described since.2-8 The condition is heterogeneous and it is often difficult to identify any common factors in the patients. Although it can occur at any age, most patients were between 20 and 40 years of age; most also had a preceding history of epilepsy, usually for many years, with no predominantly encountered aetiology. Various 
Results
The demographic and clinical features are summarised in table 1. The average age of onset of CPSE was 24 years from the onset of the underlying epilepsy. The length of the CPSE usually varied from a few days to a few weeks, with one exceptional case lasting 18 months. All the patients had partial epilepsy. All but three of the patients had repeated attacks of CPSE. Nine patients experienced between one and six attacks per month; three had infrequent episodes, one every five years, the other two episodes every six months; three had only ever had between two and four attacks; and in 11 the CPSE recurred regularly at intervals varying from weekly to twice yearly. None of the patients showed any Cyclicalfast and slow activity marked evidence of clinical or cognitive deterioration; this was in pronounced contrast to our experience with patients with convulsive status. We could only identify five patients in whom more than one psychometric evaluation had been performed over a period of two or more years, and none of the five showed any decline in any of the test scores.
A case that exemplifies the salient clinical features of CPSE in our series was that of a right-handed 25 year old male, who had complex partial and secondary generalised seizures from the age of two and began to have prolonged episodes of confusion from the age of 21 and Tomson8 collected 33 cases, estimating the annual incidence to be 1-5 in 100 000. It is not possible to arrive at a figure for incidence from our results, but our experience in a specialist neurology hospital, which sees only a selected proportion of the epilepsy population, is that up to 15% of patients who have chronic complex partial seizures have had one or more episodes of CPSE. '6 A striking feature of these cases is the tendency of the CPSE to recur, often with surprising regularity. Recurrence of CPSE has been noted before. Dunne noted that half of his patients may have had previous episodes,2 although it was not clear whether this was in the patients with absence status or CPSE. In another series, Ballinger, studying eight patients of his own and 17 from the literature, noted that eight had had previous attacks. As a result of the highly variable clinical nature of CPSE, and the difficulties of collecting retrospective information, it is probable that many reports have missed previous attacks of CPSE. In this series 11 patients had evidence of recurring attacks, and in some this was in a regular pattern, every week or every month.
Different reasons have been cited previously to explain the recurrence of attacks.
Fujiwara"7 described a patient whose episodes of CPSE were the result of non-compliance. Other stimuli for recurrence are menstruation, and even genetic factors have been implicated. 18 One of our patients had an attack of CPSE after he stopped his antiepileptic drugs. Even after they were restarted he continued to have further episodes in spite of good compliance. Another patient had been controlled with sulthiame alone, but, on removal of this drug from the UK market, he developed episodes of CPSE that have only partially responded to reintroduction of sulthiame (used on a named patient basis). In most cases, however, we were unable to identify a consistent precipitating factor, nor was the aetiology of the epilepsy similar. In spite of the repeated episodes of CPSE, the lack of evidence for either local damage or more generalised cerebral dysfunction is noteworthy when contrasted with the morbidity and mortality of convulsive status. This is unexpected because of the neurological damage from convulsive status is said to be caused by the persisting cerebral discharges and build up of excitatory neurotransmitters, rather than by hypoxia or poor cerebral perfusion which accompanies convulsive status.7 Well documented serial pyschometry was performed in only a small number of patients in this study, but there was no marked clinical evidence of cognitive decline or any other sign of neurological deterioration in the other patients. Evidence that CPSE causes serious neuronal loss has prompted most authors to recommend treating CPSE in the same way as convulsive status, if necessary with general anaesthesia to halt all cerebral EEG activity.7 This policy carries a high morbidity and should be weighed against the generally good outlook we found in our patients.
Treating the episodes of CPSE is difficult. In our series the response to intravenous benzodiazepines was variable. Three patients showed EEG and some clinical improvement, whereas one had an EEG response but remained in CPSE. One of our cases persisted in CPSE for 18 months in spite of vigorous treatment-even longer than a similar case which lasted for 7 months.19 These observations are in agreement with others about the resistance of CPSE to standard treatments.8 There is also a variable response to attempts to prevent further attacks of CPSE with anti-epileptic drugs. Although valproate may be successful in the prevention of absence status,20 this has not been substantiated in CPSE. Of our 20 patients, 19 were on standard anti-epileptic drugs, and yet they continued to have further attacks. One patient showed a worthwhile reduction in the number of CPSE episodes after starting carbamazepine, and another patient later underwent a temporal lobectomy and did not have any subsequent episodes of CPSE. Clearly, further work is needed to clarify the long term prognosis of patients with this disorder before a policy of more aggressive intervention can be recommended.
